GlassScriptPhysician profile
Nasim S Daoud
NPI 1518117795
$108,630.97
in general payments reported to CMS, 2019-2025
31 companies · $32K in 2025
The $32K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,606 · 2021: $18K · 2022: $20K · 2023: $8,872 · 2024: $14K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $19K · Consulting Fee: $9,430 · Travel and Lodging: $3,513 · Honoraria: $3,000 · Education: $82.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,500.00 |
| Food and Beverage | $19,216.45 |
| Consulting Fee | $9,430.00 |
| Travel and Lodging | $3,512.95 |
| Honoraria | $3,000.00 |
| Education | $82.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $43,085.78 | 2019-2023 | Krystexxa |
| Abbvie INC. | $32,664.20 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $9,836.59 | 2019-2025 | |
| Janssen Biotech, INC. | $5,387.85 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $3,258.33 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $3,058.69 | 2021-2025 | Otezla, Enbrel, Tavneos |
| Ani Pharmaceuticals, INC. | $1,345.33 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $1,342.22 | 2020-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $1,170.22 | 2021-2025 | Taltz, Olumiant, Zepbound |
| Aurinia Pharma U.S., INC. | $840.60 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $837.63 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $794.14 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $678.72 | 2021-2025 | Tremfya |
| Pfizer INC. | $614.02 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.20 | 2021-2025 | Ofev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $487.54 | 2021-2025 | Orencia |
| Radius Health, INC. | $487.31 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $478.44 | 2019-2023 | Actemra |
| Alexion Pharmaceuticals, INC. | $383.63 | 2022-2025 | Strensiq |
| Kyowa Kirin, INC. | $337.82 | 2023-2025 | Crysvita |
| Genzyme Corporation | $335.79 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $248.91 | 2024 | Arcalyst |
| Organon LLC | $227.18 | 2021-2024 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $69.01 | 2024-2025 | Idacio |
| Bioventus LLC | $42.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.61 | 2023 | Truxima |
| Depuy Synthes Sales INC. | $23.13 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.38 | 2021 | |
| Sandoz INC. | $13.48 | 2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $13.24 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasim Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.